
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Minneapolis Veterans Affairs Medical Center, 2 Departments of Urologic Surgery and 3 Laboratory Medicine and Pathology, and 4 The Cancer Center, University of Minnesota, Minneapolis, Minnesota
Requests for reprints: Khalil Ahmed, Cellular and Molecular Biochemistry Research Laboratory (151), Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417. Phone: 612-467-2594; Fax: 612-725-2093. E-mail: ahmedk{at}umn.edu
Protein serine/threonine kinase CK2 (formerly casein kinase 2) is a ubiquitous protein kinase that plays key roles in cell growth, proliferation, and survival. We have shown previously that its molecular down-regulation induces apoptosis in cancer cells in culture. Here, we have employed a xenograft model of prostate cancer to extend these studies to determine whether antisense CK2
evokes a similar response in vivo. A single dose of antisense CK2
oligodeoxynucleotide given directly into the PC3-LN4 xenograft tumor in nude mouse induced a dose- and time-dependent tumor cell death in vivo. The tumor was completely resolved at the higher tested dose of the antisense. Cell death was due to apoptosis and correlated with a potent down-regulation of the CK2
message and loss of CK2 from the nuclear matrix in the xenograft tissue as well as in cancer cells in culture. These observations accorded with several of the earlier studies indicating that loss of CK2 from the nuclear matrix is associated with induction of apoptosis. Comparison of the effects of antisense CK2
oligodeoxynucleotide on cancer versus normal or noncancer cells showed that the concentration of antisense CK2
that elicited extensive apoptosis in tumor cells in culture or xenograft tumors in vivo had a relatively small or minimal effect on noncancer cells in culture or on normal prostate gland subjected to orthotopic injection of antisense oligodeoxynucleotide in vivo. The basis for the difference in sensitivity of cancer versus noncancer cells to antisense CK2
is unknown at this time; however, this differential response under similar conditions of treatment may be significant in considering the potential feasibility of targeting the CK2 signal for induction of apoptosis in cancer cells in vivo. Although much further work will be needed to establish the feasibility of targeting CK2 for cancer therapy, to our knowledge, this is the first report to provide important new evidence as an initial "proof of principle" for the potential application of antisense CK2
in cancer therapy, paving the way for future detailed studies of approaches to targeting CK2 in vivo to induce cancer cell death.
Key Words: antisense CK2 prostate cancer xenograft model cell death apoptosis
This article has been cited by other articles:
![]() |
L. Wang, D. T. Sloper, S. N. Addo, D. Tian, J. W. Slaton, and C. Xing WL-276, an Antagonist against Bcl-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth Cancer Res., June 1, 2008; 68(11): 4377 - 4383. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Ahmad, N. H. Harris, A. D. Johnson, H. C.N. Lindvall, G. Wang, and K. Ahmed Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1006 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Ahmad, G. Wang, and K. Ahmed Intracellular Hydrogen Peroxide Production Is an Upstream Event in Apoptosis Induced by Down-Regulation of Casein Kinase 2 in Prostate Cancer Cells Mol. Cancer Res., May 1, 2006; 4(5): 331 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wang, K. A. Ahmad, and K. Ahmed Role of Protein Kinase CK2 in the Regulation of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells Cancer Res., February 15, 2006; 66(4): 2242 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamane and T. J. Kinsella CK2 Inhibits Apoptosis and Changes Its Cellular Localization Following Ionizing Radiation Cancer Res., May 15, 2005; 65(10): 4362 - 4367. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |